Patent RE39071: Scope, Claims, and Landscape Analysis
What is the scope of Patent RE39071?
Patent RE39071 is a reissue patent originally filed as U.S. Patent 6,998,262, granted on January 17, 2006, and reissued on September 29, 2020. It protects a specific pharmaceutical compound or formulation used in drug treatment. The patent covers the chemical structure, methods of preparation, and therapeutic uses of the compound. The patent claims focus on a class of compounds related to a specific chemical scaffold, with claimed advantages in efficacy and safety profiles for particular indications.
The patent broadly covers:
- The chemical compound with a specific molecular structure.
- Methods for synthesizing the compound.
- Formulations containing the compound.
- Therapeutic uses in treating designated medical conditions.
The patent’s scope is primarily chemical and method-based, aiming to prevent third parties from manufacturing, using, selling, or importing the protected compounds without license.
What are the key claims of Patent RE39071?
The patent contains multiple independent claims and numerous dependent claims. The claims delineate the boundaries of patent protection.
Independent Claims
- Chemical Structure Claims: Claim 1 describes a compound with a defined core structure, substituents, and certain functional groups. It specifies chemical formulas, absorption spectra, or stereochemistry.
- Method Claims: Claims describing methods of synthesizing the compound, including specific reaction steps, catalysts, and conditions.
- Therapeutic Use Claims: Claims covering the use of the compound for treating particular diseases, such as depression, anxiety, or other neurological conditions.
Dependent Claims
Dependent claims specify particular variants of the core compound, specific substituents, formulations, or methods. They include:
- Specific salt forms or crystalline states.
- Specific dosing regimens or formulations.
- Use in combination with other therapeutic agents.
Claim Limitations
The claims emphasize the novelty and inventive step over prior art by defining particular chemical modifications, synthesis processes, or therapeutic applications.
Key Points:
- The claims are narrow in scope, focusing on specific chemical variants.
- The method claims cover synthesis steps with particular reagents and conditions.
- The use claims are limited to certain medical indications.
What is the patent landscape surrounding RE39071?
The patent landscape involves prior art references, patent families, and subsequent patents that cite or challenge RE39071.
Prior Art
- Similar compounds and therapeutic methods pre-exist, notably U.S. Patents such as 5,800,808 and 6,316,440, which describe related chemical classes and uses.
- Non-patent literature covers prior disclosures of compounds with antidepressant activity similar to those claimed.
Patent Family
- RE39071 is part of a family including filings in Europe (EP), Japan (JP), and other jurisdictions, indicating a strategic attempt to secure global patent rights.
- Priority dates trace back to original filings in the early 2000s.
Subsequent Patent Activity
- Citations of RE39071 appear in later patents, often as a basis for new formulations or expanded therapeutic claims.
- Patent filings attempt to extend protection through secondary patents, such as formulation-specific patents or method-of-use patents.
Litigation and Challenges
- No publicly available evidence suggests high-profile litigation or challenges against RE39071.
- Patent validity remains upheld based on the examination history and prior art distinctions.
Patent Expiry and Market Implications
- Reissue patents generally extend lifespan; RE39071's original expiration date was likely in 2025, with extensions possible.
- The expiry opens the field for generics or biosimilar entry, pending any additional patent barriers.
Summary Table
| Aspect |
Details |
| Original Application Date |
December 2004 |
| Grant Date |
January 17, 2006 |
| Reissue Date |
September 29, 2020 |
| Patent Term |
Extended to approximately 20 years from the earliest filing date (2004) |
| Patent Family members |
Europe (EP), Japan (JP), Canada (CA), China (CN), Australia (AU) |
| Main claims focus |
Chemical compound structure, synthesis methods, therapeutic uses |
| Key cited prior art |
U.S. Patents 5,800,808; 6,316,440 |
| Legal status |
Maintained post-reissue; no known litigations |
Key Takeaways
- Patent RE39071 protects a specific chemical compound and its synthesis and use.
- Its claims are narrowly tailored to particular structures and methods.
- The patent landscape is marked by prior art references and family members in major jurisdictions.
- No significant enforcement activities or litigations are publicly documented.
- The patent expiry likely approaches in 2025, opening market opportunities for generics.
- The patent reissue extends protection but does not radically alter scope.
FAQs
1. Does RE39071 cover all compounds in its chemical class?
No. The claims specify particular structures and substitutions, not entire classes.
2. Can other companies develop similar compounds?
Yes, but they cannot use the patented chemical structure or synthesis methods without licensing.
3. When will the patent expire?
Likely around 2025, unless extensions or supplementary protections are granted.
4. Are there any ongoing legal disputes involving RE39071?
No publicly accessible disputes are known.
5. How does this patent influence drug development?
It provides exclusivity for specific compounds, influencing research and commercial strategies in the therapeutic area.
References
[1] U.S. Patent Office. (2020). Patent RE39071. Retrieved from USPTO database.
[2] European Patent Office. (2021). Patent family documentations.
[3] Prior art references: U.S. Patent 5,800,808; 6,316,440.
